Ann: Public Health Mosquito Control Partnership, page-48

BGT is ticking the right boxes with trial data and partnerships however the recent Capital Raise was poorly handled.

Tim Chapman from Henslows has been handling the investor relations for many years and imo we have continually seen share price under performance, a weak register, and continual selling pressure. Its time both go imo and a fresh approach is taken. They have 4m options expiring in November at 18c - below the IPO price.

In addition, the board should take some responsibility for the poor CR and a fresh injection onto the board would be most welcomed.

This is a solid company, in the right sector at the right time, with potential. I'm holding but a freshen up would be worthwhile imo.